Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Oct 15.

Published in final edited form as: J Neuroimmunol. 2013 Aug 1;263(0):20–27. doi: 10.1016/j.jneuroim.2013.07.009

In vivo efficacy of MVB_MOG/PLP in suppressing PLP-induced EAE. MVB_MOG/PLP-treated mice (n = 6) received three s.c. injections at a concentration of 100 nmol/100 μl on days 4, 7, and 10 and its efficacy was compared to that of PBS in mice (n = 6) treated in a similar fashion. Progress of the disease was monitored following (A) the clinical disease score, expressed as the mean clinical score ± SEM, and (B) the percent change in body weight, expressed as the mean % change in body weight ± SEM.

In vivo efficacy of MVB_MOG/PLP in suppressing PLP-induced EAE. MVB_MOG/PLP-treated mice (n = 6) received three s.c. injections at a concentration of 100 nmol/100 μl on days 4, 7, and 10 and its efficacy was compared to that of PBS in mice (n = 6) treated in a similar fashion. Progress of the disease was monitored following (A) the clinical disease score, expressed as the mean clinical score ± SEM, and (B) the percent change in body weight, expressed as the mean % change in body weight ± SEM.